D2-40 Antibody is a Specific Marker for B2 Thymomas.

Area of Science:

• Oncology
• Immunohistochemistry
• Pathology

Background:

• Recent studies link worse thymoma outcomes to podoplanin (D2-40 antibody) expression.
• Podoplanin's role in thymic epithelial tumors requires further investigation across different subtypes and stages.

Purpose of the Study:

• To investigate podoplanin expression patterns using D2-40 antibody in various thymic epithelial tumor subtypes.
• To assess the correlation between D2-40 reactivity, its reaction type (membranous vs. cytoplasmic), and clinicopathologic features like tumor type, stage, and myasthenia gravis.

Main Methods:

• Immunohistochemical analysis of 72 thymic epithelial tumors using D2-40 antibody.
• Assessment of podoplanin presence and reaction pattern (membranous or cytoplasmic).
• Statistical analysis to correlate D2-40 reactivity with tumor histologic type, stage, and myasthenic symptoms.

Main Results:

• Positive D2-40 reactivity was observed in thymoma subtypes AB (37%), B1 (40%), B2 (85%), B3 (23%), and metaplastic (100%).
• Membranous D2-40 reaction was highly specific for B2 thymomas (P<0.0001), while cytoplasmic reactivity showed a slight association with AB or B1 subtypes (P=0.0256).
• No significant correlation was found between D2-40 reactivity and tumor stage (P=0.4) or myasthenic symptoms (P=0.21).

Conclusions:

• Membranous D2-40 immunoreactivity is a highly specific marker for B2 thymomas.
• Antipodoplanin antibody reactivity in thymomas does not correlate with tumor stage or the presence of myasthenic symptoms.